National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children

This study is currently recruiting participants.
Verified August 2013 by University of British Columbia
Sponsor:
Collaborators:
Genome Canada
Genome British Columbia
Child and Family Research Institute
University of Western Ontario, Canada
Provincial Health Services Authority
Health Canada
Canada Gene Cure
Eli Lilly and Company
Pfizer
Merck Sharp & Dohme Corp.
Canadian Society of Clinical Pharmacology
Canadian Institutes of Health Research (CIHR)
Canada Foundation for Innovation
British Columbia Clinical Genomics Network
Information provided by (Responsible Party):
University of British Columbia
ClinicalTrials.gov Identifier:
NCT00414115
First received: December 19, 2006
Last updated: August 23, 2013
Last verified: August 2013
  Purpose

The purpose of the study is (1) to identify and collect samples from children and adults who take drugs and have adverse drug reactions AND children and adults who take drugs and do not experience any adverse drug effects; (2) to determine if genetic differences between the two groups contribute to causing the adverse drug reactions; and (3) to develop patient specific drug dosing guidelines to prevent future adverse drug reactions. We also wish to compare the use of prescription drugs, medical and hospital services and vital statistics between BC participants who experience adverse drug reactions and those who do not.

Study hypothesis: Genetic differences may contribute to patients' response to drugs and may be responsible for adverse drug reactions.


Condition
Adverse Drug Reaction (ADR)

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Canadian Pharmacogenomics Network for Drug Safety

Further study details as provided by University of British Columbia:

Estimated Enrollment: 7000
Study Start Date: August 2005
Estimated Study Completion Date: December 2013
Detailed Description:

CPNDS will identify ADR predictive markers by comparing DNA and plasma samples from patients that suffer ADRs with samples from control populations that are stratified by medication type and age. The GATC will obtain its clinical material for ADR patients mainly, from hospital-based active surveillance network across Canada's major hospitals.

1. CPNDS will examine known SNPs in candidate genes related to the ADR (i.e. drug metabolism genes, drug transporter genes, drug target genes, and other disease-specific genes or genes related to the physiological pathway of the ADR.) 2. CPNDS will discover novel ADR predictive SNPs and mutations by sequencing DNA samples from our patient cohorts. CPNDS will also genotype and sequence DNA samples from populations of controls that received the same drugs, but did not suffer ADRs; and a second population of control patients who represent a random sample of the population of known ethnic backgrounds.

Novel ADR predictive SNPs and mutations will be functionally validated by pharmacokinetic approaches applied to time course analysis of drug concentrations for each specific genotype. Pharmacokinetic studies will also be used to determine the drug concentration in patients to characterize possible mechanisms of the ADR, translating into rational approaches to the choice of candidate genes to be examined in the genomic analyses.

The cost-effectiveness of an ADR screening program for the prevention of ADRs in children and adults will be calculated in detailed health-economic studies.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Children under 19 years who have taken drugs and adults to replicate findings in children

Criteria

Inclusion Criteria:

  • Children under 19 years who have taken drugs.
  • Biological parents of children who have had an ADR.
  • Patients/parents who speak and understand English (except in Quebec).
  • Adults (for validation of findings in children)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00414115

Contacts
Contact: Anne Smith 604-875-3502 asmith@popi.ubc.ca

Locations
Canada, British Columbia
Children's and Women's Health Centre of British Columbia Recruiting
Vancouver, British Columbia, Canada, V6H 3V4
Contact: Anne Smith    604-875-3502    asmith@popi.ubc.ca   
Principal Investigator: Bruce Carleton, MD         
Sponsors and Collaborators
University of British Columbia
Genome Canada
Genome British Columbia
Child and Family Research Institute
University of Western Ontario, Canada
Provincial Health Services Authority
Health Canada
Canada Gene Cure
Eli Lilly and Company
Pfizer
Merck Sharp & Dohme Corp.
Canadian Society of Clinical Pharmacology
Canadian Institutes of Health Research (CIHR)
Canada Foundation for Innovation
British Columbia Clinical Genomics Network
Investigators
Principal Investigator: Bruce Carleton, Pharm. D. University of British Columbia
Principal Investigator: Michael Hayden, MD, Ph.D University of British Columbia
  More Information

Additional Information:
No publications provided by University of British Columbia

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of British Columbia
ClinicalTrials.gov Identifier: NCT00414115     History of Changes
Other Study ID Numbers: H04-70358, CW Health Centre of BC, W04-0138
Study First Received: December 19, 2006
Last Updated: August 23, 2013
Health Authority: Canada: Health Canada

Keywords provided by University of British Columbia:
Observational controlled study
Genomic biomarkers
Adverse drug reaction
In children OR adults

Additional relevant MeSH terms:
Drug Toxicity
Poisoning
Substance-Related Disorders

ClinicalTrials.gov processed this record on April 17, 2014